Charts

21 Nov, 2022
12:00
Seeking Alpha
17 Nov, 2022
23:14
Seeking Alpha

News

15 Nov, 2022
Dare Bioscience, Inc. (DARE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Grant Funds Will Support Development of a Reconstitutable Vaginal Thermosetting Gel Formulation to Ultimately Serve as a Delivery Vehicle that Allows Administration of Live Biotherapeutics at the Point of Care in a Wide Range of Settings SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has received a grant from the Bill & Melinda Gates Foundation (the foundation) of $584,986 to support activities related
14 Nov, 2022
Agile Therapeutics Inc. (NASDAQ: AGRX) is on a journey to fulfill the unmet health needs of women with products designed to provide them ...
DARE-VVA1 Demonstrated Improvement in Vaginal Cytology Parameters and Bothersome Symptoms of Vulvar and Vaginal Atrophy (VVA), Supporting Ongoing Development Investigational Therapy for Women with VVA Who Cannot, or Should Not, Take Supplemental Estrogen, Including Women with Hormone Receptor-Positive (HR+) Breast Cancer There are Currently No FDA-Approved Products Labeled for VVA Treatment for Patients with or at Risk of Recurrence of HR+ Breast Cancer SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE)
10 Nov, 2022
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 27.27% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
September 30, 2022: $40.4 million in cash and cash equivalentsOvaprene®: IDE approval from FDA for pivotal Phase 3 study; additional study design considerations being reviewed and implemented to further position the study as the single pivotal study for marketing approvalDARE-HRT1: Positive topline efficacy data from Phase 1/2 clinical studySildenafil Cream, 3.6%: Completion of subject screening for Phase 2b RESPOND clinical study Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, Nov.
09 Nov, 2022
08 Nov, 2022
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will present at the Stifel 2022 Healthcare Conference, being held November 15-16, 2022 in New York, NY. Ms. Johnson’s presentation is scheduled for Tuesday, November 15th at 9:10 a.m. Eastern Time. A live webcast of the presentation will be available at https://wsw.com/webcast/stifel74/dare/206456
03 Nov, 2022
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 10, 2022, to review its financial results for the quarter ended September 30, 2022 and to provide a Company update. To access the conference call via phone, dial (800) 715-9871 (U.S.) or (646) 307-1963 (international). The conference ID number for the call is 8
01 Nov, 2022
Approximately 160 to 170 Subjects in Total Are Expected to Complete the Clinical Study;Approximately 100 Subjects Have Completed All Study Assessments to Date Topline Data of Phase 2b RESPOND Study Targeted for 2Q-2023 If Clinical Development is Successful, Sildenafil Cream, 3.6% Has the Potential to be the First FDA-Approved FSAD Treatment Option SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Techn
25 Oct, 2022
From Evofem Biosciences Inc.’s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare Bioscience Inc.’s (NASDAQ: DARE) ...
17 Oct, 2022
DarBioscience Inc(NASDAQ: DARE) announcedtopline efficacy resultsfrom its Phase 1/2 trial of ...
Statistically Significant Results for Improvement in both the Vasomotor and the Vaginal Symptoms of Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline efficacy results from its Phase 1 / 2 clinical trial of DARE-HRT1. DARE-HRT1 is a novel, invest
10 Oct, 2022
Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive ProductSAN DIEGO, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the U.S. Food & Drug Administration (FDA) approved an Investigational Device Exemption (IDE) application allowing Daré to conduct a single arm, open-label pivotal contraceptive efficacy study of Ovaprene®, an investigational hormone-free m
15 Sep, 2022
SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in two upcoming conferences. Informa Connect Women’s Healthcare Access & Innovation Digital ConferenceSeptember 21, 2022, 1:15-1:45 PM Eastern Time Presentation: Novel Approaches to Non-Hormonal Female Contraception Sabrina Martucci Johnson, President and CEO, Daré Bioscience To
06 Sep, 2022
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a fireside chat during the H.C. Wainwright 24th Annual Global Investment Conference, a hybrid conference being held from September 12-14, 2022 in-person at the Lotte New York Palace Hotel and allowing for virtual participation. The fireside chat will occur on Monday, September
29 Aug, 2022
Study Enrollment Expected to Complete in 4Q-2022 with Approximately 150 Subjects Topline Data of Phase 2b RESPOND Study Targeted for 2Q-2023 If clinical development is successful, Sildenafil Cream, 3.6% has the potential to be the first FDA-approved FSAD treatment option SAN DIEGO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company,
24 Aug, 2022
Glycerol monolaurate has the potential to deliver broad antimicrobial activity to treat a variety of bacterial, fungal, and viral vaginal infectionsSAN DIEGO, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it has entered into a license agreement with Hennepin Life Sciences LLC under which Daré acquired the exclusive global rights to develop and commercialize treatments delivering the novel antimicrobial glycerol
12 Aug, 2022
While it may not be enough for some shareholders, we think it is good to see the Daré Bioscience, Inc. ( NASDAQ:DARE...
09 Aug, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Mersana, GSK Ink $1.36B ...
June 30, 2022: $32.1 million in cash and cash equivalentsJuly 2022: approximately $18.0 million in cash received subsequent to quarter-end: $10.0 million upfront license fee under global license agreement with Organon to commercialize XACIATOTM (clindamycin phosphate) vaginal gel, 2%, and$7.96 million under existing $48.9 million grant to fund DARE-LARC1 4Q-2022: expected U.S. commercial launch of XACIATO Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE)
08 Aug, 2022
14:16
FinancialContent
Dare Bioscience (NASDAQ:DARE) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what ...
02 Aug, 2022
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, August 9, 2022, to review its financial results for the quarter ended June 30, 2022 and to provide a Company update. To access the conference call via phone, dial (800) 715-9871 (U.S.) or (646) 307-1963 (international). The conference ID number for the call is 3817141. T
25 Jul, 2022
Gainers Strata Skin Sciences (NASDAQ:SSKN) shares increased by 16.4% to $1.28 during Monday's after-market session. Strata Skin ...
11 Jul, 2022
U.S. President Joe Biden said he had asked his administration to consider whether he has the authority to declare an abortion-related ...
08 Jul, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer, Africa CDC Strikes ...
07 Jul, 2022
Gainers Aprea Therapeutics (NASDAQ:APRE) shares increased by 36.2% to $1.09 during Thursday's after-market session. Aprea ...
SAN DIEGO, July 07, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and CEO, will be participating in a virtual panel discussion presented by Maxim Group LLC and hosted by M-Vest, on July 13, 2022 at 11:00 a.m. ET. Additional information regarding the panel is set forth below. Title: “A Tipping Point in Women’s Health - Does the SCOTUS Outcome Change the Paradigm in Contraception?”
04 Jul, 2022
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
30 Jun, 2022
Daré will receive a $10 million upfront payment from Organon An estimated 21 million American women experience bacterial vaginosis SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the exclusive license agreement entered into on March 31, 2022 with Organon (NYSE: OGN), a global women’s healthcare company, has become fully effective. Under the agreement, Organon licensed global rights to XACIATO (clindamy
27 Jun, 2022
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Evofem Biosciences is in the spotlight following the overturning of Roe v. Wade. Here's why EVFM stock is a name to watch. The post EVFM Stock: Contraception Maker Evofem Biosciences Doubles After Roe Decision appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 in savings or $5 million. Do this now.
Three days after the U.S. Supreme Court struck down Roe v. Wade in one of the most potentially impactful rulings of the last century, a ...
12 May, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BridgeBio Inks Licensing ...
10:19
FinancialContent
Dare Bioscience (NASDAQ:DARE) reported its Q1 earnings results on Thursday, May 12, 2022 at 06:00 AM. Here's what ...
11 May, 2022
14:06
FinancialContent
Dare Bioscience (NASDAQ:DARE) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to ...
31 Mar, 2022
Organon & Co(NYSE: OGN)will license global rightstoDarBioscience Inc's(NASDAQ: DARE) ...
12:36
FinancialContent
Dare Bioscience (NASDAQ:DARE) reported its Q4 earnings results on Thursday, March 31, 2022 at 08:00 AM. Here's what ...
Organon Enters into Global License Agreement to commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%)
09:25
FinancialContent
Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth ...
30 Mar, 2022
07 Jan, 2022
29 Dec, 2021
Gainers Orchard Therapeutics (NASDAQ:ORTX) stock moved upwards by 12.6% to $1.34 during Wednesday's pre-market ...
09 Dec, 2021
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock increased by 74.49% to $5.2 during Thursday's pre-market session. ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! It's time to kick off another busy day of trading with the biggest pre-market stock movers for Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...
08 Dec, 2021
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 79% to $18.63. Insignia Systems recently announced the commencement ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Penny stocks are still a hot topic among retail traders and we're covering some of the top ones to watch Wednesday that are on the move. The post Penny Stocks to Watch: What’s Going on With ZOM, DARE, PSFE, EFOI and AUUD Today? appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...
15:50
FinancialContent
If markets have memories, shares of DarBioscience, Inc. (NASDAQ: DARE) may be in trouble. The stock has run into a resistance ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We've reached the halfway point of the week and there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...
Gainers DarBioscience, Inc. (NASDAQ: DARE) rose 45.2% to $3.08 in pre-market trading after the company reported the FDA ...
07 Dec, 2021
TheFDA has approvedDarBioscience Inc(NASDAQ: DARE) Xaciato (DARE-BV1) to treat bacterial ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive ...
06 Dec, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt ...
02 Dec, 2021
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, ...
10 Nov, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To ...
28 Sep, 2021
Gainers Geovax Labs (NASDAQ:GOVX) shares rose 46.37% to $6.06 during Tuesday's after-market session. This security traded at a ...
12 Aug, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
09 Aug, 2021
TheFDA has accepted for reviewDarBioscience Inc's(NASDAQ: DARE) marketing application for DARE-BV1 for ...
Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 30.38% to $2.36 during Monday's pre-market session. The ...
08 Aug, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...
13 Jul, 2021
Gainers SCWorx (NASDAQ:WORX) stock increased by 38.34% to $3.68 during Tuesday's pre-market session. The ...
09 Jul, 2021
Gainers Galectin Therapeutics (NASDAQ:GALT) shares moved upwards by 35.0% to $3.73 during Friday's regular session. ...
08 Jul, 2021
Gainers TESSCO Technologies Incorporated (NASDAQ: TESS) shares rose 46% to $8.41 in pre-market trading after the company reported ...
09:13
FinancialContent
Gainers Newegg Commerce, Inc. (NASDAQ: NEGG) shares surged 148.4% to close at $67.57 on Wednesday after jumping around 42% on ...
07 Jul, 2021
Toward the end of trading Wednesday, the Dow traded up 0.20% to 34,647.52 while the NASDAQ rose 0.01% to 14,664.04. The S&P also ...
Longtime trader David Green thinks AMC Entertainment Holdings (NYSE: AMC), could continue to drop down to $40 a share. “I ...

Related Articles